• Lancet neurology · Oct 2019

    Review Comparative Study

    Early highly effective versus escalation treatment approaches in relapsing multiple sclerosis.

    • Daniel Ontaneda, Emma Tallantyre, Tomas Kalincik, Sarah M Planchon, and Nikos Evangelou.
    • Mellen Center for Multiple Sclerosis, Cleveland Clinic, Cleveland, OH, USA. Electronic address: ontaned@ccf.org.
    • Lancet Neurol. 2019 Oct 1; 18 (10): 973-980.

    AbstractTreatment decisions in multiple sclerosis are complex given the large number of disease-modifying therapies with diverse safety and efficacy profiles. The importance of early treatment has been recognised but how intensively to treat at onset is not known. Substantial variability exists in treatment selection with weak clinical trial evidence to guide initial treatment choices. Decision-making is made more complicated by variable tolerance for risk of side-effects and inability to accurately predict treatment response. Whether to use moderately effective and safe medications with escalation as needed, or to use higher efficacy medications from the outset, is a key question in clinical practice. Clinical trials in patients with relapsing multiple sclerosis have focused on pairwise comparisons but the effectiveness of different treatment approaches has not been tested. Future pragmatic randomised clinical trials and observational studies will help to inform more rational selection of initial therapies and improve the quality of life of patients with relapsing multiple sclerosis.Copyright © 2019 Elsevier Ltd. All rights reserved.

      Pubmed     Full text   Copy Citation     Plaintext  

      Add institutional full text...

    Notes

     
    Knowledge, pearl, summary or comment to share?
    300 characters remaining
    help        

    hide…

Want more great medical articles?

Keep up to date with a free trial of metajournal, personalized for your practice.
1,704,841 articles already indexed!

We guarantee your privacy. Your email address will not be shared.